Get the Stockscreener App
4.59
2.34%
-0.11
After Hours:
4.70
0.11
+2.40%
Prothena Corporation Plc stock is traded at $4.59, with a volume of 1.96M.
It is down -2.34% in the last 24 hours and down -52.63% over the past month.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
See More
Previous Close:
$4.70
Open:
$4.6
24h Volume:
1.96M
Relative Volume:
1.61
Market Cap:
$247.08M
Revenue:
$217.25M
Net Income/Loss:
$-50.92M
P/E Ratio:
-4.59
EPS:
-1
Net Cash Flow:
$-100.85M
1W Performance:
-30.24%
1M Performance:
-52.63%
6M Performance:
-71.68%
1Y Performance:
-77.29%
1-Day Range:
$4.4216
$4.70
1-Week Range:
$4.32
$5.35
52-Week Range:
$4.32
$25.42
Prothena Corporation Plc Stock (PRTA) Company Profile
Name
Prothena Corporation Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corporation Plc
|
4.59 | 354.18M | 217.25M | -50.92M | -100.85M | -1.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corporation Plc Stock (PRTA) Latest News
Piper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial Discontinuation - MSN
Prothena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Chardan Capital Decreases Earnings Estimates for Prothena - Defense World
Citizens JMP Slashes Prothena (PRTA) to $29 from $78 After AFFIRM-AL Trial Fails - MSN
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - Insider Monkey
FY2027 EPS Estimates for Prothena Decreased by HC Wainwright - Defense World
Prothena (NASDAQ:PRTA) Given “Underperform” Rating at Bank of America - Defense World
Bank of America Reiterates “Underperform” Rating for Prothena (NASDAQ:PRTA) - Defense World
Prothena (NASDAQ:PRTA) Earns “Underperform” Rating from Bank of America - Defense World
The Prothena Corporation plc (NASDAQ:PRTA) Analysts Have Been Trimming Their Sales Forecasts - simplywall.st
BofA cuts Prothena stock rating, slashes target to $4 By Investing.com - Investing.com Nigeria
Prothena Corp (PRTA) Sees Downgrade and Price Target Cut by B of A Securities | PRTA Stock News - GuruFocus
Oppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from Outperform - Insider Monkey
BofA Securities Downgrades Prothena to Underperform From Neutral, $4 Price Target - marketscreener.com
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | P - GuruFocus
Prothena (PRTA) Faces Downgrade After Clinical Trial Setback | PRTA Stock News - GuruFocus
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down - MSN
Prothena (PRTA) Downgraded by BofA Analyst with Lower Price Target | PRTA Stock News - GuruFocus
Prothena (NASDAQ:PRTA) Price Target Lowered to $81.00 at Piper Sandler - Defense World
Prothena (NASDAQ:PRTA) Price Target Cut to $29.00 by Analysts at JMP Securities - Defense World
Prothena (NASDAQ:PRTA) Lowered to Hold Rating by Jefferies Financial Group - Defense World
Prothena (NASDAQ:PRTA) Given New $14.00 Price Target at HC Wainwright - Defense World
Traders Purchase High Volume of Put Options on Prothena (NASDAQ:PRTA) - Defense World
Prothena (PRTA) Shares Plunge After Key Trial Setback - GuruFocus
Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place (PRTA) - Seeking Alpha
Peninsula biotech Prothena falters — again — and layoffs are on the waySan Francisco Business Times - The Business Journals
Prothena Shares Fall, Stock Downgraded by Multiple Research Firms After Birtamimab Development Discontinued - marketscreener.com
Prothena Corp (PRTA) Downgraded by Oppenheimer | PRTA Stock News - GuruFocus
Jefferies Downgrades Prothena Corporation (PRTA) After Negative Trial Results - Insider Monkey
Prothena stock hits 52-week low amid downgrades (PRTA:NASDAQ) - Seeking Alpha
Prothena Corp (PRTA) Sees Target Price Reduction by Piper Sandler | PRTA Stock News - GuruFocus
Piper Sandler cuts Prothena stock target to $81 from $110 By Investing.com - Investing.com UK
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Cantor Fitzgerald cuts Prothena stock rating to Neutral By Investing.com - Investing.com UK
Prothena Corp (PRTA) Target Price Slashed by JMP Securities | PRTA Stock News - GuruFocus
Prothena (PRTA) Downgraded Following Unsuccessful Phase 3 Trial | PRTA Stock News - GuruFocus
Expert Outlook: Prothena Corp Through The Eyes Of 5 Analysts - Benzinga
Prothena Corp (PRTA) Analyst Update: Price Target Significantly Lowered | PRTA Stock News - GuruFocus
Why Is Prothena Stock Trading Lower On Tuesday? - Benzinga
Jefferies Downgrades Prothena to Hold From Buy, Adjusts Price Target to $6 From $32 - marketscreener.com
Prothena Corp (PRTA) Price Target Lowered by HC Wainwright & Co. | PRTA Stock News - GuruFocus
Prothena stock price target cut to $14 at H.C. Wainwright By Investing.com - Investing.com UK
Chardan Adjusts PT on Prothena to $18 From $40 After Drug Removal From Model, Keeps Buy Rating - marketscreener.com
Prothena (PRTA) Price Target Slashed Following Clinical Trial Ou - GuruFocus
Prothena (PRTA) Faces Price Target Cut Following Trial Results | PRTA Stock News - GuruFocus
Prothena (PRTA) Target Price Slashed Following Study Setback | P - GuruFocus
Prothena (PRTA) Faces Setback with AFFIRM-AL Trial Results | PRTA Stock News - GuruFocus
Jefferies Downgrades Prothena (PRTA) Following Study Setback | P - GuruFocus
Prothena (PRTA) Downgraded by Oppenheimer After Trial Results | PRTA Stock News - GuruFocus
Oppenheimer cuts Prothena stock rating after trial setback By Investing.com - Investing.com South Africa
Jefferies cuts Prothena stock rating to hold, slashes target to $6 By Investing.com - Investing.com UK
Prothena Corporation Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):